Boston Scientific (BSX) AI Stock Analysis

• Market Cap: $141.74B
• Dividend Yield: N/A
• Average Volume (3M): 10.04M
• Price to Earnings (P/E): 51.6
• Beta (1Y): 0.84
• Revenue Growth: 21.62%
• EPS Growth: 54.80%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 1,482,442,000
• 10 Day Avg. Volume: 12,931,153
• 30 Day Avg. Volume: 10,039,194
• PEG Ratio: 4.27
• Price to Book (P/B): 6.04
• Price to Sales (P/S): 7.85
• P/FCF Ratio: 49.69
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 8.48
• Enterprise Value/Gross Profit: 13.42
• Enterprise Value/Ebitda: 33.29
• 1Y Price Target: $126.35
• Price Target Upside: 31.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 23
• EPS Forecast (FY): 3.04
• Revenue Forecast (FY): $20.07B

• Rating: 79 Outperform
• Price Target: $115.00 ▲(19.26% Upside)

Boston Scientific's overall stock score is driven by strong financial performance and positive earnings call outcomes. While the technical analysis and valuation present some concerns, the company's robust growth trajectory and raised guidance support a favorable outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Boston Scientific's products, enhancing its market position and supporting long-term financial health.

Product Success

The success of key products like WATCHMAN demonstrates Boston Scientific's innovation and ability to capture market share, driving future growth.

Cash Flow Management

Strong cash flow management ensures liquidity and financial flexibility, enabling Boston Scientific to invest in growth opportunities and withstand economic fluctuations.

Negative Factors

EMEA Region Challenges

Operational challenges in EMEA could hinder growth in this region, potentially impacting overall revenue and necessitating strategic adjustments.

Urology Segment Growth

Slower growth in the urology segment may limit Boston Scientific's ability to capitalize on market opportunities, affecting segment profitability.

China Market Pressure

Regulatory pressures in China, such as VBP, could constrain sales growth in this key market, impacting Boston Scientific's global revenue potential.

Boston Scientific Business Overview & Revenue Model

Company Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Boston Scientific generates revenue primarily through the sale of its medical devices, which are used in a variety of procedures across multiple specialties. The company operates through several key segments, including Cardiovascular, Rhythm Management, MedSurg, and Neuromodulation, each contributing to its overall revenue. Major revenue streams include sales of implantable devices, surgical tools, and diagnostic equipment. Additionally, Boston Scientific benefits from strategic partnerships and collaborations with healthcare providers, hospitals, and research institutions, which enhance its distribution capabilities and expand its market reach. The company also invests in research and development to innovate and introduce new products, which serves as a significant driver of future revenue growth.

Boston Scientific Financial Statement Overview

Summary

Boston Scientific exhibits strong financial performance with robust revenue growth, healthy profit margins, and efficient cash management. The balance sheet shows moderate leverage and effective equity utilization, contributing to financial stability.

Income Statement

Boston Scientific has demonstrated strong revenue growth with a 5.36% increase in TTM, supported by healthy gross and net profit margins of 63.23% and 13.53% respectively. The EBIT and EBITDA margins are robust at 18.37% and 23.67%, indicating efficient operational management. Overall, the company shows a positive growth trajectory and profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.54, indicating moderate leverage. The return on equity stands at 11.49%, showcasing effective utilization of equity to generate profits. The equity ratio of 53.94% suggests a solid equity base relative to total assets, contributing to financial stability.

Cash Flow

Cash flow analysis reveals a strong free cash flow growth rate of 15.25% in TTM, highlighting improved cash generation capabilities. The operating cash flow to net income ratio of 0.83 and free cash flow to net income ratio of 0.77 indicate efficient cash conversion and healthy liquidity. Overall, cash flow management appears robust.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.49B	16.75B	14.24B	12.68B	11.89B	9.91B
Gross Profit	11.69B	10.27B	8.83B	7.71B	7.46B	5.58B
EBITDA	4.71B	3.94B	3.45B	2.74B	2.52B	1.51B
Net Income	2.50B	1.85B	1.59B	698.00M	1.04B	-82.00M
Balance Sheet
Total Assets	41.56B	39.40B	35.14B	32.47B	32.23B	30.78B
Cash, Cash Equivalents and Short-Term Investments	534.00M	414.00M	865.00M	928.00M	1.93B	1.73B
Total Debt	12.03B	11.15B	9.49B	9.28B	9.45B	9.54B
Total Liabilities	18.91B	17.39B	15.61B	14.90B	15.61B	15.45B
Stockholders Equity	22.42B	21.77B	19.28B	17.57B	16.62B	15.33B
Cash Flow
Free Cash Flow	3.31B	2.65B	1.70B	914.00M	1.32B	1.13B
Operating Cash Flow	4.29B	3.44B	2.50B	1.53B	1.87B	1.51B
Investing Cash Flow	-6.76B	-5.69B	-2.57B	-2.01B	-1.60B	-411.00M
Financing Cash Flow	114.00M	1.81B	5.00M	-548.00M	-95.00M	293.00M

Boston Scientific Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 96.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Neutral. The current price of 96.43 is above the 20-day moving average (MA) of 96.35, below the 50-day MA of 98.55, and below the 200-day MA of 100.95, indicating a neutral trend. The MACD of -1.25 indicates Negative momentum. The RSI at 49.68 is Neutral, neither overbought nor oversold. The STOCH value of 83.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BSX.

Boston Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	80 Outperform	$126.45B	26.64	9.81%	2.76%	5.34%	13.15%
BSX	79 Outperform	$141.74B	51.58	12.66%	―	21.62%	54.80%
EW	79 Outperform	$49.71B	36.84	13.59%	―	0.19%	65.58%
ABT	73 Outperform	$218.14B	15.74	30.62%	1.88%	6.37%	142.39%
ZBH	73 Outperform	$17.66B	22.06	6.41%	1.05%	5.47%	-23.03%
SYK	70 Outperform	$135.84B	46.64	14.04%	0.95%	10.95%	-18.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Boston Scientific Corporate Events

Boston Scientific Approves 2026 Bonus Plan

On November 18, 2025, Boston Scientific‘s Board of Directors approved the 2026 Annual Bonus Plan and two performance share programs, aiming to align executive compensation with company performance and shareholder interests. The bonus plan and performance share programs, effective from January 1, 2026, to December 31, 2028, are designed to incentivize employees based on company-wide metrics such as global sales, earnings, and sustainability goals, with potential impacts on executive compensation through policies like the Dodd-Frank Clawback Policy.

John E. Sununu to Leave Boston Scientific Board

On October 22, 2025, John E. Sununu announced he will not seek re-election to Boston Scientific‘s Board of Directors at the 2026 Annual Meeting. Sununu, who has been a board member since 2009, will continue his roles until then, with his decision not stemming from any disagreement with the company. The board will assess the need for new directors following his departure.